Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.
Chana Weinstock(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Michael H. Brave(United States Food and Drug Administration), Harpreet Singh(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Sundeep Agrawal(Center for Drug Evaluation and Research), Kirsten B. Goldberg(United States Food and Drug Administration), Laura L. Fernandes(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Yang‐Min Ning(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration)
Cited by 4
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k